首页> 美国卫生研究院文献>Cancer Science >Effects of Chemoendocrine Therapy on the Coagulation‐Fibrinolytic Systems in Patients with Advanced Breast Cancer
【2h】

Effects of Chemoendocrine Therapy on the Coagulation‐Fibrinolytic Systems in Patients with Advanced Breast Cancer

机译:化学内分泌疗法对晚期乳腺癌患者凝血-纤溶系统的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In order to predict a hypercoagulable state in patients with advanced breast cancer receiving medical treatment, the effects of Chemoendocrine therapy on the coagulation‐flbrinolytic systems were investigated prospectively. The patients were randomly divided into two groups. The ACT group had 38 patients, who received 20 mg/m2 adriamycin (ADM) i.v. on days 1 and 8, 100 mg cyclophosphamide (CPA) p.o. on days 1–14, and 20 mg tamoxifen (TAM) p.o. daily. The ACM group had 44 patients, who received 20 mg/m2 ADM i.v. on days 1 and 8, 100 mg CPA p.o. on days 1–14 and 1200 mg medroxyprogesterone acetate (MPA) p.o. daily. The treatment was repeated every 28 days until there was evidence of progressive disease or until the full ADM dose (550 mg/m2) had been given. The following 9 hematologic parameters were measured every 4 weeks: alpha 2‐plasmin inhibitor plasmin complex (PIC), anti‐thrombin‐III (AT‐III), D‐dimer (Dd), fibrinogen (Fg), plasminogen (Pg), protein C (PC), thrombin‐antithrombin‐III complex (TAT‐III), tissue plasminogen activator (t‐PA), and factor × (FX). Compared to the ACT group, patients in the ACM group showed significantly higher values of AT‐III and PC, which exceeded the normal ranges. The levels of Pg, t‐PA and FX were significantly higher in the ACM group than in the ACT group, but were still within the normal ranges. The levels of TAT‐III, Dd and PIC decreased in the ACT group and were unchanged in the ACM group after the start of treatment. Fg remained unchanged in both groups after the start of treatment. One patient in the ACM group had thrombophlebitis of the lower extremities with high levels of TAT‐III, Dd and PIC and a decrease of Fg, but her condition returned to normal after reduction of the MPA dose. Although these data are not directly indicative of a hypercoagulable state in patients receiving Chemoendocrine therapy, changes in AT‐III, TAT‐III, Dd and PIC should be monitored carefully when this type of treatment is given.
机译:为了预测接受治疗的晚期乳腺癌患者的高凝状态,前瞻性研究了化学内分泌疗法对凝血纤溶系统的影响。将患者随机分为两组。 ACT组有38例患者,他们接受了20 mg / m 2 阿霉素(静脉注射)治疗。在第1天和第8天,口服100 mg环磷酰胺(CPA)。第1至14天,以及口服20 mg他莫昔芬(TAM)。日常。 ACM组有44例患者,他们接受了20 mg / m 2 ADM静脉注射。在第1和8天,每次100 mg CPA。第1-14天和口服1200 mg醋酸甲羟孕酮(MPA)。日常。每28天重复一次治疗,直到有进行性疾病的证据或完全给予ADM剂量(550 mg / m 2 )。每4周测量以下9种血液学参数:α2-纤溶酶抑制剂纤溶酶复合物(PIC),抗凝血酶III(AT-III),D-二聚体(Dd),纤维蛋白原(Fg),纤溶酶原(Pg),蛋白C(PC),凝血酶-抗凝血酶III复合物(TAT-III),组织纤溶酶原激活物(t-PA)和因子×(FX)。与ACT组相比,ACM组患者的AT-III和PC值明显更高,超过了正常范围。 ACM组的Pg,t-PA和FX水平明显高于ACT组,但仍处于正常范围内。开始治疗后,ACT组中TAT-III,Dd和PIC的水平下降,而ACM组中的水平保持不变。开始治疗后,两组的Fg均保持不变。 ACM组中的一名患者患有下肢血栓性静脉炎,TAT-III,Dd和PIC含量较高,Fg降低,但在降低MPA剂量后她的病情恢复了正常。尽管这些数据不能直接表明接受化学内分泌治疗的患者出现高凝状态,但是在进行此类治疗时应仔细监测AT-III,TAT-III,Dd和PIC的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号